



"In³ Europe: A Preview of Early-Stage Medtech Companies"

September 20-21, 2005 · Brussels, Belgium
Crowne Plaza Hotel, Brussels City Centre

medtech  insight
a division of Windhover Information

Medical Tactile Inc. Looks to Quantify Traditional Manual Palpation in Breast Cancer Screening

by Ronald C. Trahan

Medical Tactile Inc. ("MTI") is an emerging medical device company headquartered in Los Angeles. MTI was founded to develop, manufacture and market the application of **tactile sensing technology** as an adjunctive device for the traditional physical breast exam. The Company's technology is based on the research of its Chief Technology Officer, Dr. Jae Son, a graduate of Harvard University, where he earned his doctorate in Engineering Sciences. A *tactile sensor* consists of an array of pressure transducers that produce a digital signal as the sensor is pressed and moved against tissue. The MTI tactile sensor technology provides greater sensing sensitivity and repeatability than competing technologies and is more sensitive than the human sense of touch. Using advanced, proprietary image-processing algorithms, the Company's first product, the **SureTouch Visual Mapping System**, extracts salient lesion information from raw tactile images. This provides physicians with key information about the lesion without the need for extensive training in image interpretation and ultimately enables them to make informed real-time decisions regarding patient referral and course of care.




DR. JAE SON
Chief Technology Officer
Medical Tactile Inc.


"We are committed to creating an affordable, fast and easy-to-use device that will enhance and quantify the traditional process of manual palpation in breast cancer screening," says Steve Weiss, MTI's CEO. Weiss has successfully managed technology companies for over 25 years by serving as CEO and in other senior executive positions for medical device companies from inception to successful IPO and/or acquisition. From 1990 through 1998 he served as a member of the Board of Directors and Chief Executive Officer of Lumisys, Inc., where he executed a successful IPO in November 1995 (NASDAQ:LUMI) before the company was acquired by Eastman Kodak in late 2000. Prior to that time, Weiss was a co-founder and Board Member of Virtual Imaging, a medical imaging company, where he last held the position of President (1985-1990).

"We are tremendously excited about presenting at Medtech Insight's first In³ meeting in Europe. We are keenly aware of the fact that Medtech Insight's In³ conferences not only draw hundreds of high-quality investors, but also pull numerous business development executives from among all of the significant companies in the industry. Thus, it will be a great opportunity for us to impress the right kind of investors," says Weiss.


Mammography



Ultrasound



SureTouch



The SureTouch probe detects differences in the underlying tissues by measuring reaction pressures. Preliminary research indicates that MTI's high resolution sensors have the ability to obtain significantly higher sensitivity than is achievable with manual palpation. SureTouch is a technological achievement that can provide the first independent confirmation and documentation of Clinical Breast Exams (CBEs) with a potential to reduce breast cancer morbidity and possibly mortality.

What the experts are saying about Medtech Insight's first In³ Europe event:



"I am attending the first In³ event in Europe because it will include some of the biggest dealmakers in the industry, as well as major medtech, biopharma and biotech companies. Obviously, a superb environment in which to tap into many opportunities about to emerge in the medtech space."

Antoine Papiernik
Managing Partner
Sofinnova Partners
Paris, France



"Medtech Insight's first foray into the European community will showcase technologies and products being developed by emerging companies from Europe, Israel and the U.S.—all of whom are seeking strategic partners and/or investment. Companies and investors alike will benefit."

Berthold Hackl
Managing Partner
Heidelberg Innovation
Heidelberg, Germany



"Medtech Insight's conferences always attract top-shelf investors, including, of course, the business development executives from major companies in the industry. We fully expect to attract meaningful attention at the Brussels venue in September."

Nick Yeo
President and CEO
Vascular Reconditioning
Snoqualmie, WA

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small companies, both public and private.

Investment In Innovation (In³) Europe: A Preview of Early-Stage Medical Technology Companies Crowne Plaza Hotel, Brussels City Centre, Brussels, Belgium, September 20-21, 2005

Medtech Insight's In³ conferences have drawn a total of more than 4,800 senior execs from the investment community and major medtech companies, and have featured more than 560 innovative early-stage presenting companies. In³ Europe will feature a new group of over 50 early-stage medical technology companies from around the world seeking partnering and/or investment.

To register for this conference, please call 949-219-0150 or 888-290-2225 (toll-free in the U.S.), send an email to in3@medtechinsight.com, or register online at www.medtechinsight.com.